MARKET

NKTR

NKTR

Nektar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.12
-0.06
-0.37%
Opening 11:56 09/16 EDT
OPEN
16.21
PREV CLOSE
16.18
HIGH
16.21
LOW
15.87
VOLUME
142.76K
TURNOVER
--
52 WEEK HIGH
26.75
52 WEEK LOW
12.92
MARKET CAP
2.96B
P/E (TTM)
-6.1445
1D
5D
1M
3M
1Y
5Y
Director Of Nektar Therapeutics Trades $544.92 Thousand In Company Stock
Robert Chess, Director at Nektar Therapeutics (NASDAQ:NKTR), made a large buy and sell of company shares on September 9, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Robert Chess...
Benzinga · 3d ago
B of A Securities Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $18
B of A Securities analyst Greg Harrison initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $18.
Benzinga · 5d ago
Even after rising 9.3% this past week, Nektar Therapeutics (NASDAQ:NKTR) shareholders are still down 77% over the past three years
It's not possible to invest over long periods without making some bad investments. But you want to avoid the really big...
Simply Wall St. · 09/02 16:03
How Bad Are Nektar Therapeutics's Earnings? | Return on Capital Employed
Benzinga Pro data, Nektar Therapeutics (NASDAQ:NKTR) reported Q2 sales of $28.33 million. Earnings fell to a loss of $110.20 million, resulting in a 0.74% decrease from last quarter.
Benzinga · 09/02 15:30
RedHill Reports Second Quarter 2021 Results
(Nasdaq:RDHL) ('RedHill' or the 'Company'), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the second quarter ended June 30, 2021.
ACCESSWIRE · 08/26 11:31
Highland Capital Management Fund Advisors, L.p. ...
GuruFocus News · 08/24 15:38
Insider Trends: Insider Prolongs 90-Day Selling Trend at Nektar Therapeutics
MT Newswires · 08/18 19:21
Insider Trends: Nektar Therapeutics Insider Extends 90-Day Selling Trend
MT Newswires · 08/18 19:18
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NKTR. Analyze the recent business situations of Nektar through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NKTR stock price target is 29.91 with a high estimate of 80.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 422
Institutional Holdings: 199.68M
% Owned: 108.64%
Shares Outstanding: 183.80M
TypeInstitutionsShares
Increased
76
5.43M
New
25
874.40K
Decreased
78
6.75M
Sold Out
22
1.14M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
-0.61%
Key Executives
Non-Executive Chairman/Independent Director
Robert Chess
Chief Executive Officer/President/Director
Howard Robin
Chief Financial Officer/Chief Operating Officer/Senior Vice President
Gilbert Labrucherie
Senior Vice President - Finance/Chief Accounting Officer
Jillian Thomsen
Senior Vice President/General Counsel
Mark Wilson
Senior Vice President
Brian Kotzin
Senior Vice President
John Northcott
Senior Vice President
Dimitry Nuyten
Other
Jonathan Zalevsky
Lead Director/Independent Director
Roy Whitfield
Independent Director
Jeff Ajer
Independent Director
Myriam Curet
Independent Director
Karin Eastham
Independent Director
R. Scott Greer
No Data
  • All
  • Financials
  • Insiders
More
About NKTR
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.

Webull offers kinds of Nektar Therapeutics stock information, including NASDAQ:NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.